

Romualdo Barroso-Sousa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3269800/publications.pdf>

Version: 2024-02-01

92
papers

4,063
citations

201674

27
h-index

123424

61
g-index

93
all docs

93
docs citations

93
times ranked

6375
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Cancer Research, 2022, 82, OT1-14-02-OT1-14-02.	0.9	1
2	Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). Cancer Research, 2022, 82, GS2-10-GS2-10.	0.9	22
3	Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i). Cancer Research, 2022, 82, P4-01-06-P4-01-06.	0.9	2
4	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
5	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 141-153.	2.4	5
6	Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell, 2022, 185, 1694-1708.e19.	28.9	100
7	Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications. Frontiers in Immunology, 2022, 13, 816642.	4.8	18
8	Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: A GBECAM multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, e18822-e18822.	1.6	0
9	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	3.0	11
10	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1105-1118.	7.0	24
11	Abstract PD9-08: Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. , 2021, , .		0
12	Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC). , 2021, , .		0
13	Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond. BioDrugs, 2021, 35, 159-174.	4.6	30
14	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Medicine, 2021, 13, 89.	8.2	10
15	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer, 2021, 7, 110.	5.2	20
16	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	12.8	19
17	Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist, 2021, 26, 927-933.	3.7	5
18	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. Npj Breast Cancer, 2021, 7, 120.	5.2	9

#	ARTICLE	IF	CITATIONS
19	Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. <i>Lancet Oncology</i> , The, 2021, 22, e474-e487.	10.7	38
20	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 238-245.	2.4	44
21	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	5.0	60
22	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	7.1	84
23	Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 923-930.	2.4	5
24	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. <i>Current Treatment Options in Oncology</i> , 2020, 21, 59.	3.0	12
25	Prevalence and mutational determinants of high tumor mutation burden in breast cancer. <i>Annals of Oncology</i> , 2020, 31, 387-394.	1.2	244
26	Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	7.0	138
27	Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2390-2397.	1.6	9
28	Abstract P3-09-10: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC). , 2020, , .		3
29	Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study. , 2020, , .		2
30	Genomic profiling of breast cancer brain metastases reveals targetable alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2525-2525.	1.6	0
31	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , 2019, 15, 2463-2470.	2.4	12
32	<p></p>Evidence to date: talazoparib in the treatment of breast cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5177-5187.	2.0	30
33	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	3.4	44
34	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. <i>Stem Cell Investigation</i> , 2019, 6, 4-4.	3.0	1
35	The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. <i>Annals of Oncology</i> , 2019, 30, 575-581.	1.2	18
36	Gut Microbiome and Breast Cancer in the Era of Cancer Immunotherapy. <i>Current Breast Cancer Reports</i> , 2019, 11, 272-276.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology, 2019, 3, 1-9.	3.0	4
38	Deescalating Treatment in the Adjuvant Setting in Low-Risk HER2-Positive Breast Cancer. , 2019, , 135-142.		0
39	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocrine Reviews, 2019, 40, 17-65.	20.1	349
40	Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1004-1004.	1.6	19
41	Genomic landscape of de novo stage IV breast cancer.. Journal of Clinical Oncology, 2019, 37, 1022-1022.	1.6	3
42	A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1047-1047.	1.6	5
43	Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS1115-TPS1115.	1.6	12
44	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. Journal of the Endocrine Society, 2019, 3, .	0.2	0
45	Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.. Journal of Clinical Oncology, 2019, 37, 517-517.	1.6	0
46	De-escalating treatment in the adjuvant setting in HER2-positive breast cancer. Future Oncology, 2018, 14, 937-945.	2.4	5
47	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer, 2018, 124, 1111-1121.	4.1	72
48	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. JAMA Oncology, 2018, 4, 173.	7.1	753
49	Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Global Oncology, 2018, 4, 1-9.	0.5	8
50	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Current Oncology Reports, 2018, 20, 1.	4.0	30
51	Optimal treatment of early stage HER2-€positive breast cancer. Cancer, 2018, 124, 4455-4466.	4.1	52
52	Database Selection and Heterogeneity-€More Details, More Credibility-€Reply. JAMA Oncology, 2018, 4, 1295.	7.1	2
53	Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.. Journal of Clinical Oncology, 2018, 36, 1010-1010.	1.6	12
54	A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.. Journal of Clinical Oncology, 2018, 36, 1068-1068.	1.6	3

#	ARTICLE	IF	CITATIONS
55	A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, TPS1100-TPS1100.	1.6	0
56	A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS1119-TPS1119.	1.6	0
57	Wnt/beta-catenin pathway: modulating anticancer immune response. Journal of Hematology and Oncology, 2017, 10, 101.	17.0	448
58	Reply to Garcia J. etÂal.. Breast, 2017, 34, 132.	2.2	1
59	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunology Research, 2017, 5, 1133-1140.	3.4	114
60	High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. Oncotarget, 2017, 8, 49470-49483.	1.8	24
61	PD-1 inhibitors in endometrial cancer. Oncotarget, 2017, 8, 106169-106170.	1.8	15
62	CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer. Translational Cancer Research, 2017, 6, S205-S209.	1.0	1
63	Abstract OT1-01-09: Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen. , 2017, , .		0
64	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. Ecancermedicalscience, 2016, 10, 609.	1.1	30
65	Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Therapeutic Advances in Medical Oncology, 2016, 8, 261-266.	3.2	93
66	Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care, 2016, 11, 167-173.	1.4	92
67	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast, 2016, 30, 136-140.	2.2	4
68	Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis. PLoS ONE, 2016, 11, e0148142.	2.5	282
69	Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and Clinical Oncology, 2015, 3, 793-796.	1.0	27
70	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget, 2015, 6, 34221-34227.	1.8	198
71	Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2â” locally advanced breast cancer. Brazilian Journal of Medical and Biological Research, 2015, 48, 479-485.	1.5	9
72	Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 192, 86-89.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2015, 32, 443.	2.5	16
74	Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 835-841.	1.5	3
75	Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Medical Oncology</i> , 2014, 31, 264.	2.5	47
76	Acute Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib. <i>Clinics and Practice</i> , 2014, 4, 635.	1.4	13
77	Complete Resolution of Hypercortisolism with Sorafenib in a Patient with Advanced Medullary Thyroid Carcinoma and Ectopic ACTH (Adrenocorticotrophic Hormone) Syndrome. <i>Thyroid</i> , 2014, 24, 1062-1066.	4.5	29
78	Cardiac Safety of (Neo)Adjuvant Trastuzumab in the Community Setting: A Single-Center Experience. <i>Breast Care</i> , 2014, 9, 255-260.	1.4	6
79	Exploring the role of metformin in anticancer treatments: A systematic review. <i>Drugs of Today</i> , 2014, 50, 623.	1.1	20
80	Role of paclitaxel and platinum-based chemotherapy in locally advanced and metastatic penile squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15624-e15624.	1.6	0
81	Pretreatment neutrophil to lymphocyte ratio and prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15144-e15144.	1.6	0
82	Biological therapies in breast cancer: Common toxicities and management strategies. <i>Breast</i> , 2013, 22, 1009-1018.	2.2	26
83	Decreased levels of alpha-1-acid glycoprotein are related to the mortality of septic patients in the emergency department. <i>Clinics</i> , 2013, 68, 1134-1139.	1.5	19
84	Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features.. <i>Journal of Clinical Oncology</i> , 2013, 31, 476-476.	1.6	0
85	Oral Metronomic Cyclophosphamide in Patients with Metastatic Castration-Resistant Prostate Cancer Stratified by Prior Docetaxel Therapy. <i>Annals of Oncology</i> , 2012, 23, ix308.	1.2	0
86	Intoxicação grave por paraquat: achados clínicos e radiológicos em um sobrevivente. <i>Jornal Brasileiro De Pneumologia</i> , 2010, 36, 513-516.	0.7	22
87	Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1615-1622.	3.5	39
88	Sleep disturbances in patients on maintenance hemodialysis: role of dialysis shift. <i>Revista Da Associação Médica Brasileira</i> , 2007, 53, 492-496.	0.7	51
89	Vatairea macrocarpa (Leguminosae) lectin activates cultured macrophages to release chemotactic mediators. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 374, 275-282.	3.0	22
90	Glutamine and alanyl-glutamine accelerate the recovery from 5-fluorouracil-induced experimental oral mucositis in hamster. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 215-222.	2.3	34

#	ARTICLE	IF	CITATIONS
91	Glutamine depletion potentiates leucocyte-dependent inflammatory events induced by carrageenan or Clostridium difficile toxin A in rats. Immunology, 2005, 116, 328-336.	4.4	7
92	Quiescent Cancer Cells Resist T Cell Attack by Forming an Immunosuppressive Niche. SSRN Electronic Journal, 0, , .	0.4	2